Skip to main content Skip to section navigation Skip to footer

Home
Our story
Our focus
Our portfolio
For investors
- Company
- Stock
- SEC filings
- Governance
- Analysts
- News
- Events
Contact us
Sign up for email alerts

For investors

Company
Stock
SEC filings
Governance
Analysts
News
Events

News

search Search close

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance
Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease
Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Relmada Therapeutics Provides Corporate Update
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023
Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
Relmada Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 23, 2022
Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Relmada Therapeutics Announces Publication of REL-1017 Phase 2 Study Results in The American Journal of Psychiatry
Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
Relmada Therapeutics to Present Data at the 60th Annual Meeting of the American College of Neuropsychopharmacology
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
Relmada Therapeutics to Present at the Jefferies London Healthcare Conference
Relmada Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress
Relmada Therapeutics Provides Regulatory and Development Updates on Ongoing Late-Stage Clinical Program for REL-1017 for Treatment of Major Depressive Disorder
Relmada Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Relmada Therapeutics to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 10, 2021
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC
Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting
Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference
Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021
Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting
Relmada Therapeutics Announces Participation in the 7th Annual Truist Securities Life Sciences Summit
Relmada Therapeutics Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021
Relmada Therapeutics Announces Initiation of Second Pivotal Phase 3 Study of REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 23, 2021
Relmada Therapeutics Announces Participation in the Oppenheimer 31st Annual Healthcare Conference
Relmada Therapeutics Announces Participation in the 2021 SVB Leerink Global Healthcare Conference
Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder
Relmada Therapeutics to Participate in Upcoming Investor Conferences
Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market®
Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms
Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference
Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
Relmada Therapeutics to Present at Biotech Showcase 2019
Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Australia Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms
Relmada Therapeutics Announces $6.9 Million Private Placement
Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program
Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors
Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company
Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder
Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference
Relmada Therapeutics to Participate in BIO CEO and Investor Conference
Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone
Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER
Relmada Therapeutics to Present at Biotech Showcase 2017
Relmada Therapeutics to Present at LD Micro "Main Event" Investor Conference
Relmada Therapeutics to Present at the Sidoti & Company Fall 2016 Emerging Growth Convention
Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms
Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum
Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston
Relmada Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Relmada Therapeutics to Present at the 2016 Aegis Growth Conference
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
Pharmaceutical Industry Leader Ronald M. Burch Joins Relmada Therapeutics Advisory Team
Relmada Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
Relmada Therapeutics Secures First European Patent Covering LevoCap ER
Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression
Relmada Therapeutics' d-Methadone Receives Orphan Drug Designation for Management of Postherpetic Neuralgia
Relmada Therapeutics to Present at the LD Micro Invitational Conference
Relmada Therapeutics to Present at the 5th Annual Marcum MicroCap Conference
Relmada Therapeutics Announces Promotion of Michael D. Becker to Chief Financial Officer
Relmada Therapeutics Announces Results of In Vivo Study Showing d-Methadone has Antidepressant-like Effects
Relmada Therapeutics to Present at the Joseph Gunnar "Pioneers 2016" Conference
Relmada Therapeutics Provides Additional Details Regarding Upcoming R&D Day
Relmada Therapeutics to Showcase Breadth of Pipeline at Upcoming R&D Day
Relmada Therapeutics, Inc. Provides Update on Nasdaq Up-Listing Process
Relmada Therapeutics to Present at the 28th Annual ROTH Conference
Relmada Therapeutics Announces Publication of Full Results from Phase I Study Showing Treatment with d-Methadone to be Safe and Well Tolerated
Relmada Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
Relmada Therapeutics Files Amended Complaint Against Laidlaw and Its Principals, Matthew Eitner and James Ahern
Relmada Therapeutics Selected to Present at 2016 Biotech Showcase™ in San Francisco
Relmada Therapeutics Successfully Completes Multiple Ascending Dose Study of d-Methadone for Neuropathic Pain
Relmada Therapeutics Announces Results of Annual Meeting of Stockholders
Relmada Therapeutics Recommends Stockholders Vote "FOR" Relmada's Director Nominees on the WHITE Proxy Card Today
U.S. Federal Court Grants Preliminary Injunction Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
Relmada Sends Letter To Stockholders Highlighting Significant Progress In Value Creation Strategy Overseen By Board And Management Team
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Relmada Stockholders Vote the WHITE Proxy Card "FOR" Relmada's Director Nominees: Shreeram Agharkar and Maged Shenouda
Pharmaceutical Industry Leader James Dolan Joins Relmada Therapeutics Advisory Team
U.S. Federal Court Issues Temporary Restraining Order Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern
Relmada Therapeutics Announces Additional Information Regarding Positive Topline Results for Proof-of-Concept Study with BuTab
Relmada Therapeutics Announces Positive Topline Results for Proof-of-Concept Study with BuTab
Relmada Therapeutics Files Federal Lawsuit Against Laidlaw & Company and its Principals Matthew Eitner and James Ahern to Protect Interests of Relmada Stockholders
Relmada Therapeutics to Mail Letter to Stockholders Highlighting Laidlaw & Company's Questionable Business Practices and Conduct
Relmada Therapeutics to Present at LD Micro Main Event
Relmada Therapeutics Strengthens its Board of Directors with the Appointment of Maged Shenouda and Paul Kelly
Relmada Therapeutics Responds to 13D Filing by Laidlaw
Relmada Therapeutics to Present at 14th Annual BIO Investor Forum
Relmada Therapeutics Announces Management Promotions
Relmada Therapeutics to Present at Aegis 2015 Growth Conference
Relmada Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference
Relmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL™ - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
Relmada Therapeutics to Participate in Two Upcoming Investor Conferences
Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist
Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
Relmada Therapeutics to Present at 2015 BIO International Convention
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference
Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine
Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017)
Relmada Therapeutics Appoints Lisa Nolan, Ph.D. as Senior Vice President of Business Development
Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine
Relmada Therapeutics Reports Positive Phase 1 Results for NMDA Receptor Antagonist d-Methadone
/C O R R E C T I O N -- Relmada Therapeutics, Inc./
Relmada Therapeutics to Present at Future Leaders in the Biotech Industry Conference
Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles
Relmada Therapeutics to Present at ROTH Capital Partners 27th Annual Growth Stock Conference
Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Novel Oral Formulations of Buprenorphine
Relmada Therapeutics to Present at the 17th Annual BIO CEO & Investor Conference
Relmada Therapeutics Selects MepiGel Formulations to Advance Into Clinical Studies
Relmada Therapeutics to Present at 11th Annual Noble Financial Capital Markets Equity Conference
Relmada Therapeutics Reaches Midway Point in Dose Escalation for Phase One Study of Novel NMDA Receptor Antagonist d-Methadone
Relmada Therapeutics to Present at OneMedForum in San Francisco
Relmada Therapeutics to Provide Corporate Update at 2015 Biotech Showcase™ in San Francisco
Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone
Relmada Therapeutics Announces Results of Annual Shareholders Meeting
Relmada Therapeutics Appoints Christine Silverstein as Director of Investor Relations
Relmada Therapeutics Nominated for Buzz of BIO Contest at the 2015 BIO CEO & Investor Conference
Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study of d-Methadone
Relmada Therapeutics To Present At LD MICRO Conference
Relmada Therapeutics Appoints Michael Becker As Senior Vice President Of Finance And Corporate Development
Relmada Therapeutics Adds $15 Million in Capital to Expedite Development of Pain Treatment Drugs
Relmada Therapeutics Reinforces Balance Sheet With $15.2 Million From Exercise Of Warrants
New Report Initiates Coverage on New Public Biopharmaceutical Company, Relmada Therapeutics, Inc.
Relmada Therapeutics Appoints Julie J. Chen As Director of Finance and Operations
Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development
Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
Relmada Announces The Filing Of Clinical Trial Application In Canada For d-methadone
Relmada Therapeutics, Inc. Provides Its First Corporate Update as a Public Company
Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker

NEWS - Aug 6, 2014

Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker

Read more

Previous Page
Page 1
—
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24

rss_feed News RSS

Sign up for alerts

Our story
Our focus
Our portfolio
For investors
- Company
- Stock
- SEC filings
- Governance
- Analysts
- News
- Events
Contact us

©2025 Relmada Therapeutics, Inc. | Privacy Policy Terms of Use